66 citations
- Chalmers University of TechnologySE9 papers
- AstraZeneca (United Kingdom)GB4 papers
- Lund UniversitySE3 papers
- Centre National de la Recherche ScientifiqueFR2 papers
- Helmholtz MunichDE2 papers
- Leiden UniversityNL2 papers
- Medical University of ViennaAT2 papers
- Novartis (Switzerland)CH2 papers
- Target (Germany)DE2 papers
- University of CambridgeGB2 papers
- University of GothenburgSE2 papers
- AstraZeneca (Finland)FI1 paper
4 papers · 1 filter
Modern approaches for evaluating treatment effect heterogeneity from clinical trials and observational data
Ilya Lipkovich, David Svensson, Bohdana Ratitch +1
In this paper we review recent advances in statistical methods for the evaluation of the heterogeneity of treatment effects (HTE), including subgroup identification and estimation…
On model-based time trend adjustments in platform trials with non-concurrent controls
Marta Bofill Roig, Pavla Krotka, Carl-Fredrik Burman +9
Platform trials can evaluate the efficacy of several treatments compared to a control. The number of treatments is not fixed, as arms may be added or removed as the trial progresse…
A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching
José L. Jiménez, Julia Niewczas, Alexander Bore +1
In confirmatory cancer clinical trials, overall survival (OS) is normally a primary endpoint in the intention-to-treat (ITT) analysis under regulatory standards. After the tumor pr…
Optimizing Trial Designs for Targeted Therapies
Thomas Ondra, Sebastian Jobjörnsson, Robert A. Beckman +4
An important objective in the development of targeted therapies is to identify the populations where the treatment under consideration has positive benefit risk balance. We conside…